Erectile dysfunction and diabetes are two of the most common conditions affecting middle-aged men in Singapore, and they share a relationship that most men — and many clinicians — do not discuss clearly enough.
Singapore’s diabetes burden is substantial. According to the Ministry of Health’s National Population Health Survey 2023–2024, 9.1% of Singapore residents aged 18 to 74 have diabetes.[1] Prevalence rises sharply with age: from 1.9% in men aged 30 to 39, to 21.8% in those aged 60 to 69, to approximately one in four men aged 70 to 74.[1] Among those with known diabetes, approximately 61.3% were not meeting the recommended glycaemic control target of HbA1c ≤7%.[1]
Into that picture, consider this: a 2024 umbrella review in BMC Public Health, which pooled data from 108,030 male diabetic patients across multiple systematic reviews and meta-analyses, found that the global pooled prevalence of erectile dysfunction in diabetic men was 65.8% — meaning roughly two in three men with diabetes experience erectile dysfunction.[2]
These two figures, read together, carry a clear clinical message. In Singapore, a meaningful proportion of men currently living with diabetes are also living with erectile dysfunction — and many of them will not have made the connection between the two, or discussed it with a doctor.
This article explains why the two conditions are so closely linked, what the underlying mechanisms are, how diabetes changes the assessment and treatment picture for erectile dysfunction, and why the symptom warrants attention rather than acceptance.
If you have not had your blood glucose checked recently and have risk factors — family history, weight around the abdomen, age over 40 — that check is a simple starting point.
Why diabetes causes erectile dysfunction
The relationship between diabetes and erectile dysfunction is not coincidental. Diabetes damages the body in ways that directly impair erectile function, through two distinct but often overlapping mechanisms: vascular damage and nerve damage.
Vascular damage: the endothelial pathway
Erections depend on blood flow — specifically on the ability of blood vessels in the penis to dilate rapidly in response to sexual arousal, allowing blood to fill the corpus cavernosum and produce an erection. This process is mediated by nitric oxide, released from the endothelial lining of penile blood vessels.
Chronic hyperglycaemia — persistently elevated blood glucose — damages the endothelium throughout the body. In the penile circulation, this produces a reduced capacity to generate nitric oxide, impaired vasodilation, and a diminished erectile response. Advanced glycation end-products (AGEs), which accumulate in diabetic tissue, further quench available nitric oxide and amplify oxidative stress, compounding the endothelial impairment.[3]
The same pathological process underlies both diabetic erectile dysfunction and diabetic macrovascular disease — including coronary artery disease and peripheral arterial disease. Erectile dysfunction in a diabetic man is therefore not an isolated sexual health problem. It is a manifestation of the same vascular disease that damages the heart and limbs, often appearing earlier because penile arteries are smaller and more sensitive to early endothelial injury.
Nerve damage: the autonomic pathway
The second major pathway is neurological. Diabetic neuropathy — damage to peripheral and autonomic nerve fibres caused by prolonged hyperglycaemia — impairs the nerve signals required to initiate and sustain an erection.
Erection is initiated by parasympathetic autonomic nerve activity. Diabetic autonomic neuropathy disrupts these signals, impairing both the neurally-mediated release of nitric oxide in penile tissue and the reflex arc that produces erection in response to sexual stimulation. Somatic neuropathy affecting penile sensory fibres reduces the sensitivity of the glans, further blunting the erectile response.[3]
In practice, most diabetic men with erectile dysfunction have elements of both vascular and neurogenic impairment. The relative contribution of each varies between individuals and changes as the disease progresses. This is clinically important because it affects both the expected response to treatment and the urgency of addressing glycaemic control as part of management.
The two mechanisms: Vascular — endothelial dysfunction reduces nitric oxide availability and penile blood flow. Neurogenic — autonomic neuropathy disrupts the nerve signals required to initiate and sustain erection. Most diabetic men with ED have both components.
The mechanism behind ED in diabetic men is not the same as in non-diabetic men, and the management differs accordingly. A doctor who understands both the metabolic and sexual health picture is better placed to advise than one who addresses them separately.
The Singapore context
The Singapore-specific picture makes this clinical relationship particularly important to address.
The landmark population-based study of erectile dysfunction in Singapore men — Tan JK et al., published in the Singapore Medical Journal in 2003, involving 729 men aged 30 and above — identified diabetes mellitus as one of the most significant independent risk factors for erectile dysfunction on multivariate analysis, alongside cardiac disease and advancing age.[4]
This was a local population study, not a global extrapolation, and its findings have remained the primary local reference for erectile dysfunction epidemiology in Singapore for over two decades.
The significance of that finding has not diminished. If anything, it has grown. Singapore’s diabetes prevalence has risen since 2003, and the diabetic population is ageing. The SingHealth Diabetes Registry, which tracks over 208,000 diabetic individuals across Singapore’s largest public healthcare cluster, shows that 84.1% have hypertension and 86.2% have hyperlipidaemia as co-morbidities.[5] These conditions further compound both the cardiovascular and erectile risks already conferred by diabetes.
The same registry analysis found that patients with poorer glycaemic control — defined as HbA1c above 8% — represented 19.5% of the diabetic population, and that this group was more likely to be younger with higher BMI.[5] This is the demographic most likely to present with erectile dysfunction as an early, unrecognised complication rather than a late sequela. The symptom in a 45-year-old man with poorly controlled type 2 diabetes is not the same clinical picture as in a 65-year-old with established macrovascular disease — even if the presenting complaint is identical.
Erectile dysfunction as an early warning in diabetic men
In men without diabetes, erectile dysfunction can serve as an early marker of cardiovascular risk because penile arteries, being smaller, are more sensitive to early endothelial disease than coronary arteries. In diabetic men, the relationship is more complex but no less clinically informative.
Erectile dysfunction may be the first symptom a diabetic man notices that indicates his glucose control is inadequate. It may precede other diabetic complications — retinopathy, nephropathy, peripheral neuropathy — by several years, particularly in men with moderate rather than severe hyperglycaemia. A 2025 comprehensive narrative review in Endocrinology, Diabetes & Metabolism confirmed that the prevalence of erectile dysfunction is estimated to be over 3.5 times higher in men with diabetes compared to those without, and that the pathophysiology reflects a complex neurovascular disorder in which metabolic injury of peripheral and autonomic nerves interacts with microvascular damage.[3]
A man who presents with erectile dysfunction and has not been tested for diabetes may have undiagnosed type 2 diabetes. A man who presents with erectile dysfunction and has known diabetes may have inadequately controlled glycaemia, subclinical autonomic neuropathy, or early microvascular disease — none of which will be apparent without appropriate assessment. The symptom is an entry point, not just a complaint to manage.
Clinical implication: In a diabetic man presenting with erectile dysfunction, the symptom is worth investigating as a potential indicator of glycaemic control adequacy and early microvascular or autonomic complications — not just treating symptomatically.
The evidence that better glucose control improves sexual function is clear. If you have been told your diabetes is 'under control' but have not discussed sexual function with your doctor, that conversation is worth initiating.
What a proper assessment looks like
The assessment of erectile dysfunction in a diabetic man requires a broader lens than the standard erectile dysfunction workup.
Glycaemic review
The most important question is whether glucose is adequately controlled. HbA1c provides a three-month average of blood glucose; a result above 7% in a man with erectile dysfunction should prompt a conversation about optimising glycaemic management, not just prescribing a PDE5 inhibitor. Improving glucose control does not immediately reverse established erectile dysfunction, but it slows further vascular and neurological damage and creates the conditions in which treatment is more likely to be effective.
Cardiovascular risk assessment
Because diabetic erectile dysfunction and diabetic cardiovascular disease share a common pathophysiology, the assessment of a diabetic man with erectile dysfunction should include a cardiovascular risk review: blood pressure, lipid profile, smoking history, family history of premature cardiovascular disease, and BMI. This is not an additional burden — it is part of standard diabetic care that may be overdue.
Assessment for autonomic neuropathy
Signs of autonomic neuropathy — postural hypotension, resting tachycardia, impaired heart rate variability, sweating abnormalities — suggest that neurogenic erectile dysfunction may be a significant component. This matters for treatment planning because men with significant autonomic neuropathy have reduced response to PDE5 inhibitors.
Hormonal assessment
Hypogonadism — low testosterone — is significantly more common in diabetic men than in the general population, driven by the metabolic effects of insulin resistance and adiposity on the hypothalamic-pituitary-gonadal axis. A hormonal panel including total testosterone, LH, and FSH is appropriate where there is reduced libido alongside erectile dysfunction, or where initial treatment response is poor.
Treatment: what is different in diabetic men
The treatment of erectile dysfunction in diabetic men follows the same framework as in non-diabetic men — PDE5 inhibitors as first-line pharmacological therapy, lifestyle modification, and addressing underlying contributors — but with important differences in expected outcomes and the role of glycaemic management.
PDE5 inhibitors
Sildenafil, tadalafil and the other PDE5 inhibitors are effective in diabetic men with erectile dysfunction, but response rates are lower than in non-diabetic men. A 2025 comprehensive narrative review confirmed that PDE5 inhibitors are the primary pharmacological treatment for diabetic ED, but that neuropathic involvement represents a major determinant of therapeutic failure — because diabetic autonomic neuropathy impairs nitric oxide bioavailability and neural transmission within the erectile pathway, blunting the response to a drug that amplifies rather than creates nitric oxide signalling.[3] Men who do not respond adequately to a PDE5 inhibitor at standard doses should be assessed for the severity of neuropathy rather than simply switching agents.
Glycaemic optimisation as part of treatment
This is the most important distinction from erectile dysfunction management in non-diabetic men. In a diabetic man, improving glycaemic control is a treatment for erectile dysfunction — not just a background health goal. Reducing chronic hyperglycaemia reduces the ongoing accumulation of advanced glycation end-products, attenuates oxidative stress in penile tissue, and slows the progression of endothelial and neurological damage. It will not reverse established structural changes, but it can arrest their progression and improve the physiological environment in which pharmacological treatment operates.
Weight loss and metabolic management
For overweight and obese diabetic men, weight loss has a direct beneficial effect on erectile function through multiple pathways: improved insulin sensitivity and glycaemic control, reduced aromatase activity (which elevates oestrogen and suppresses testosterone in adipose tissue), lower blood pressure, and improved endothelial function. The effect of significant weight loss on erectile function in diabetic men is meaningful and, in some cases, sufficient to restore function without pharmacological treatment.
Treatment of hypogonadism where present
Where low testosterone is confirmed as a contributor, testosterone replacement therapy may be appropriate alongside glycaemic management and PDE5 inhibitor therapy. The decision requires accurate diagnosis, a full hormonal assessment, and careful discussion of the risks, benefits, and monitoring requirements — the same framework as for testosterone therapy in any context.
The practical point
For a Singaporean man with diabetes and erectile dysfunction, the symptom deserves a proper clinical response — not reassurance that it is an expected consequence of getting older with diabetes.
Two in three diabetic men globally experience erectile dysfunction. In Singapore, where diabetic prevalence is high, glycaemic control is often suboptimal, and the cultural pressure to dismiss sexual health concerns remains real, many of those men are living with a treatable symptom that reflects an undertreated underlying condition.
The right approach is to treat the erectile dysfunction seriously, investigate it properly, optimise the diabetes management that is driving it, and address the cardiovascular risk that accompanies both. That is not a specialised programme. It is good medicine applied to a common clinical presentation.
If you have diabetes and have noticed changes in sexual function, speak to a doctor — the connection is direct and the management options are real. If you have ED and have never been assessed for diabetes, that assessment is also worth doing. In Singapore, one in eleven adults has diabetes, and many do not know it yet.
- Ministry of Health Singapore. National Population Health Survey 2023–2024. Singapore: MOH; 2025. moh.gov.sg.
- Kitaw TA, Abate BB, Tilahun BD, Yilak G, Rede MB, Getie A, Haile RN. The global burden of erectile dysfunction and its associated risk factors in diabetic patients: an umbrella review. BMC Public Health. 2024 Oct 14;24(1):2816. doi:10.1186/s12889-024-20300-7. PMID: 39402470. PMC11472474.
- Hostnik M, Kramberger SK, Lah L, Kmetec A, Vodenik B, Drnovsek M, Janez A, Goricar K, Dolzan V, Plaper H, Jensterle M. Erectile dysfunction in diabetes mellitus: a comprehensive narrative review of pathophysiology, genetic association studies and therapeutic approaches. Endocrinol Diabetes Metab. 2025;8(5):e70099. doi:10.1002/edm2.70099. PMC12441930.
- Tan JK, Hong CY, Png DJC, Liew LCH, Wong ML. Erectile dysfunction in Singapore: prevalence and its associated factors — a population-based study. Singapore Med J. 2003 Jan;44(1):20–26. PMID: 12762559.
- Lim LLS, Tan CS, Kwan YH, Fong W, Thumboo J, Low LL, Yoon S. Establishment of the SingHealth Diabetes Registry. Clin Diabetes Endocrinol. 2021;7(1):4. doi:10.1186/s40842-021-00117-4. PMC7982443.